| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Institute of Medical Microbiology, University of Regensburg, Regensburg, Germany;
Department of Medicine III with Institute of Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany;
Partners AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129; and
§
AIDS Office, Department of Public Health, San Francisco, CA 94140
It has been hypothesized that sequence variation within CTL epitopes leading to immune escape plays a role in the progression of HIV-1 infection. Only very limited data exist that address the influence of biologic characteristics of CTL epitopes on the emergence of immune escape variants and the efficiency of suppression of HIV-1 by CTL. In this report, we studied the effects of HIV-1 CTL epitope sequence variation on HIV-1 replication. The highly conserved HLA-B14-restricted CTL epitope DRFYKTLRAE in HIV-1 p24 was examined, which had been defined as the immunodominant CTL epitope in a long-term nonprogressing individual. We generated a set of viral mutants on an HX10 background differing by a single conservative or nonconservative amino acid substitution at each of the P1 to P9 amino acid residues of the epitope. All of the nonconservative amino acid substitutions abolished viral infectivity and only 5 of 10 conservative changes yielded replication-competent virus. Recognition of these epitope sequence variants by CTL was tested using synthetic peptides. All mutations that abrogated CTL recognition strongly impaired viral replication, and all replication-competent viral variants were recognized by CTL, although some variants with a lower efficiency. Our data indicate that this CTL epitope is located within a viral sequence essential for viral replication. Targeting CTL epitopes within functionally important regions of the HIV-1 genome could limit the chance of immune evasion.
This article has been cited by other articles:
|
|
 |
|
  H. Korthals Altes, R. de Boer, and M. Boerlijst Role of avidity and breadth of the CD4 T cell response in progression to AIDS Proc R Soc B, July 7, 2006; 273(1594): 1697 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Turnbull, A. R. Lopes, N. A. Jones, D. Cornforth, P. Newton, D. Aldam, P. Pellegrino, J. Turner, I. Williams, C. M. Wilson, et al. HIV-1 Epitope-Specific CD8+ T Cell Responses Strongly Associated with Delayed Disease Progression Cross-Recognize Epitope Variants Efficiently J. Immunol., May 15, 2006; 176(10): 6130 - 6146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Someya, Y. Ami, T. Nakasone, Y. Izumi, K. Matsuo, S. Horibata, K.-Q. Xin, H. Yamamoto, K. Okuda, N. Yamamoto, et al. Induction of Positive Cellular and Humoral Immune Responses by a Prime-Boost Vaccine Encoded with Simian Immunodeficiency Virus gag/pol J. Immunol., February 1, 2006; 176(3): 1784 - 1795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. W. Peyerl, H. S. Bazick, M. H. Newberg, D. H. Barouch, J. Sodroski, and N. L. Letvin Fitness Costs Limit Viral Escape from Cytotoxic T Lymphocytes at a Structurally Constrained Epitope J. Virol., December 15, 2004; 78(24): 13901 - 13910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. A. Jones, X. Wei, D. R. Flower, M. Wong, F. Michor, M. S. Saag, B. H. Hahn, M. A. Nowak, G. M. Shaw, and P. Borrow Determinants of Human Immunodeficiency Virus Type 1 Escape from the Primary CD8+ Cytotoxic T Lymphocyte Response J. Exp. Med., November 15, 2004; 200(10): 1243 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zhang, R. Fayad, X. Wang, D. Quinn, and L. Qiao Human Immunodeficiency Virus Type 1 Gag-Specific Mucosal Immunity after Oral Immunization with Papillomavirus Pseudoviruses Encoding Gag J. Virol., October 1, 2004; 78(19): 10249 - 10257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Masemola, T. N. Mashishi, G. Khoury, H. Bredell, M. Paximadis, T. Mathebula, D. Barkhan, A. Puren, E. Vardas, M. Colvin, et al. Novel and Promiscuous CTL Epitopes in Conserved Regions of Gag Targeted by Individuals with Early Subtype C HIV Type 1 Infection from Southern Africa J. Immunol., October 1, 2004; 173(7): 4607 - 4617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Draenert, C. L. Verrill, Y. Tang, T. M. Allen, A. G. Wurcel, M. Boczanowski, A. Lechner, A. Y. Kim, T. Suscovich, N. V. Brown, et al. Persistent Recognition of Autologous Virus by High-Avidity CD8 T Cells in Chronic, Progressive Human Immunodeficiency Virus Type 1 Infection J. Virol., January 15, 2004; 78(2): 630 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Koelle, Z. Liu, C. L. McClurkan, R. C. Cevallos, J. Vieira, N. A. Hosken, C. A. Meseda, D. C. Snow, A. Wald, and L. Corey Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor PNAS, October 28, 2003; 100(22): 12899 - 12904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Muhl, M. Krawczak, P. ten Haaft, G. Hunsmann, and U. Sauermann MHC Class I Alleles Influence Set-Point Viral Load and Survival Time in Simian Immunodeficiency Virus-Infected Rhesus Monkeys J. Immunol., September 15, 2002; 169(6): 3438 - 3446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yusim, C. Kesmir, B. Gaschen, M. M. Addo, M. Altfeld, S. Brunak, A. Chigaev, V. Detours, and B. T. Korber Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation J. Virol., July 29, 2002; 76(17): 8757 - 8768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Deml, A. Bojak, S. Steck, M. Graf, J. Wild, R. Schirmbeck, H. Wolf, and R. Wagner Multiple Effects of Codon Usage Optimization on Expression and Immunogenicity of DNA Candidate Vaccines Encoding the Human Immunodeficiency Virus Type 1 Gag Protein J. Virol., November 15, 2001; 75(22): 10991 - 11001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Leutenegger, F. S. Boretti, C. N. Mislin, J. N. Flynn, M. Schroff, A. Habel, C. Junghans, S. A. Koenig-Merediz, B. Sigrist, A. Aubert, et al. Immunization of Cats against Feline Immunodeficiency Virus (FIV) Infection by Using Minimalistic Immunogenic Defined Gene Expression Vector Vaccines Expressing FIV gp140 Alone or with Feline Interleukin-12 (IL-12), IL-16, or a CpG Motif J. Virol., November 15, 2000; 74(22): 10447 - 10457. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
